SEBI bars Rajesh Exports MD over alleged ₹15.15 lakh cr revenue misstatement; stock hits lower circuit
SEBI's interim order accuses Rajesh Mehta of misrepresenting ₹15.15 lakh crore in revenue and routing funds via Swiss subsidiary Valcambi across FY21-FY25, with 97-99% of revenue booked through overseas subs. Mehta denies all findings. Shares locked at 5% lower circuit at ₹103.92.
What happened
SEBI passed an interim order barring Rajesh Exports MD Rajesh Mehta from securities dealings, alleging ₹15.15 lakh crore revenue misrepresentation and
Key facts
- ₹15.15 lakh crore
- 97-99% revenue from overseas subs
- 5% stock fall
- ₹103.92 lower circuit
- FY2020-21 to FY2024-25
Why this matters
Distressed-asset and bullion-supply-chain opportunities may surface as Rajesh Exports' Valcambi-linked operations come under scrutiny — track regulatory milestones for potential carve-out, partnership, or share-overhang entry points.